Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Alzheimer's disease (AD) is an inflammatory neurodegenerative disease that may be associated with prior bacterial infections. Microbial "old friends" can suppress exaggerated inflammation in response to disease-causing infections or increase clearance of pathogens such as Mycobacterium tuberculosis, which causes tuberculosis (TB). One such "old friend" is Mycobacterium vaccae NCTC 11659, a soil-derived bacterium that has been proposed either as a vaccine for prevention of TB, or as immunotherapy for the treatment of TB when used alongside first line anti-TB drug treatment.
Objective: The goal of this study was to use a hypothesis generating approach to explore the effects of M. vaccae on physiological changes in the plasma and cerebrospinal fluid (CSF).
Methods: Liquid chromatography-tandem mass spectrometry-based proteomics were performed in plasma and CSF of adult male rats after immunization with a heat-killed preparation of M. vaccae NCTC 11659 or borate-buffered saline vehicle. Gene enrichment analysis and analysis of protein-protein interactions were performed to integrate physiological network changes in plasma and CSF. We used RT-qPCR to assess immune and metabolic gene expression changes in the hippocampus.
Results: In both plasma and CSF, immunization with M. vaccae increased proteins associated with immune activation and downregulated proteins corresponding to lipid (including phospholipid and cholesterol) metabolism. Immunization with M. vaccae also increased hippocampal expression of interleukin-4 (IL-4) mRNA, implicating anti-inflammatory effects in the central nervous system.
Conclusion: M. vaccae alters host immune activity and lipid metabolism. These data are consistent with the hypothesis that microbe-host interactions may protect against possible infection-induced, inflammation-related cognitive impairments.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3233/JAD-200568 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
An LC-MS/MS Assay of Irsenontrine, a Novel Phosphodiesterase‑9 Inhibitor, in Human Plasma, Urine and Cerebrospinal Fluid for Application to Clinical Pharmacokinetic Studies.
ACS Omega
September 2025
Global Drug Metabolism and Pharmacokinetics, Eisai Co., Ltd.Tokodai 5-1-3, Tsukuba, Ibaraki 300-2635, Japan.
Irsenontrine is a novel phosphodiesterase-9 inhibitor that has been developed for the treatment of cognitive dysfunction. To assess the pharmacokinetics, excretion, and distribution of the drug in humans, comprehensive assays for irsenontrine were developed using liquid chromatography with tandem mass spectrometry (LC-MS/MS) in three human matrices, including plasma, urine, and cerebrospinal fluid (CSF). Irsenontrine was extracted from the matrices by a straightforward protein precipitation method and subsequently separated on a reverse-phase column.
View Article and Find Full Text PDFEpstein-Barr virus and cytomegalovirus co-infections and mortality risk in patients with HIV-associated cryptococcal meningitis: a post-hoc analysis of a prospective nested cohort in the AMBITION-cm randomised controlled trial.
Lancet HIV
September 2025
Department of Clinical Research, London School of Hygiene and Tropical Medicine, London, UK; Botswana Harvard Health Partnership, Gaborone, Botswana.
Background: HIV-associated cryptococcal meningitis case fatality remains greater than 25%. Co-prevalent infections might contribute to poor outcomes. We aimed to ascertain the prevalence and the clinical significance of Epstein-Barr virus (EBV) and cytomegalovirus co-infections in patients with cryptococcal meningitis to guide potential therapeutic interventions.
View Article and Find Full Text PDFPotential diagnostic markers in Alzheimer's disease: current perspectives and future directions.
Neurodegener Dis Manag
September 2025
Innovation Center for Neurological Disorders and Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China.
Alzheimer's disease (AD), the most common form of dementia, remains a leading neurodegenerative disorder that necessitates the development of diagnostic markers. While current cerebrospinal fluid (CSF) and positron emission tomography (PET) biomarkers facilitate diagnostic accuracy, their invasive and pricey nature limits widespread application. Blood-based biomarkers, such as plasma Aβ42/40 and phosphorylated tau isoforms, are emerging as accessible alternatives.
View Article and Find Full Text PDFNetwork meta-analysis on the efficacy of different interventions for treating thin endometrium.
Front Endocrinol (Lausanne)
September 2025
Center of Reproductive Medicine, Yulin Maternal and Child Health Hospital, Yulin, China.
Background: The incidence of thin endometrium in assisted reproductive technology (ART) is between 1% and 2.5%, yet its treatment options are varied and often show limited efficacy. There is an urgent need to delineate the relative effectiveness of various interventions to guide clinical practice.
View Article and Find Full Text PDFPreliminary observations of glucose metabolism dysregulation in pediatric Huntington's disease.
Front Neurol
August 2025
Department of Pediatric Neuroscience, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.
Background: Pediatric Huntington's disease (PHD), a rare and severe form of juvenile-onset Huntington's disease (JOHD), is associated with highly expanded CAG repeats in the gene and a rapidly progressive neurodegenerative course. Recent studies have suggested that glucose metabolism may be impaired in PHD due to reduced expression of glucose transporters in the brain, resembling aspects of GLUT1 Deficiency Syndrome (GLUT1DS).
Methods: We investigated glucose metabolism in two pediatric patients with genetically confirmed PHD (CAG repeats: 76 and 79) referred to our tertiary care center.